WO2014112663A1 - Composition pharmaceutique pour prévenir et traiter la pancréatite chronique comprenant un extrait de nardostachys jatamansi en tant que substance active - Google Patents

Composition pharmaceutique pour prévenir et traiter la pancréatite chronique comprenant un extrait de nardostachys jatamansi en tant que substance active Download PDF

Info

Publication number
WO2014112663A1
WO2014112663A1 PCT/KR2013/000357 KR2013000357W WO2014112663A1 WO 2014112663 A1 WO2014112663 A1 WO 2014112663A1 KR 2013000357 W KR2013000357 W KR 2013000357W WO 2014112663 A1 WO2014112663 A1 WO 2014112663A1
Authority
WO
WIPO (PCT)
Prior art keywords
chronic pancreatitis
pharmaceutical composition
extract
persimmon
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2013/000357
Other languages
English (en)
Korean (ko)
Inventor
황성연
박성주
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Bio Medical Science Institute Co Ltd
Original Assignee
Korea Bio Medical Science Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Bio Medical Science Institute Co Ltd filed Critical Korea Bio Medical Science Institute Co Ltd
Priority to PCT/KR2013/000357 priority Critical patent/WO2014112663A1/fr
Publication of WO2014112663A1 publication Critical patent/WO2014112663A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a novel use of persimmon scent, and more particularly to a pharmaceutical composition for the prevention and treatment of chronic pancreatitis, and a food composition for the prevention and improvement of chronic pancreatitis comprising the extract as an active ingredient.
  • CP chronic pancreatitis
  • the syndromes, such as abdominal pain, steatorrhea, and weight loss are exacerbated by psychosocial problems, which can lead to debilitating rectal discharge, drug addiction, and loss of health care resources (Apte, MV et al. (2010)). J. Gastroenterol. Hepatol. 25 , 1816-1826).
  • CP is mainly associated with alcohol abuse (Lankisch, PG et al. (1993) Digestion 54 , 148-155).
  • Alcoholic acute pancreatitis (AP) rarely occurs after one binge drinking, so the majority of patients are men who consume 150 g of alcohol daily on average for 10-15 years after the start of the example.
  • Persimmon Scent (Nardostachys jatamansi, NJ) has been used extensively as a tonic, stimulant and anticonvulsant in several Asian countries, as well as to treat epilepsy, pathological excitement, palpitations and cramps (Bagchi, A. , Et al., Planta Med., 57, 9697 (1991)).
  • the rooted water of the incense incense has been used for mental disorders, insomnia, blood disorders and circulatory disorders (Uniyal, MR., Et al., J. Res. Indian Med.
  • the present inventors have previously reported that sweet persimmon has a protective effect on acute pancreatitis, and pneumonia (Bae, GS et al. (2010) Pancreas 39 , 520-529; Bae, GS et al. (2011) J. Nat. Med. 65 , 63 -72).
  • NJ has been used in mental disorders, obscurity, blood diseases, and the circulatory system (Uniyal. MR and Issar, RK (1969) J. Res. Indian Med. 4 , 83).
  • NJ Nardostachys jatamansi belonging to the Valerianaceae is not known for its ability to improve alcoholic chronic pancreatitis (ACP).
  • the present inventors while studying the other effects of the sensational fragrance, using an alcohol model repeatedly added to the AP effect of NJ on the ACP, morphological and histological changes of the pancreas, in vivo and in vitro ( The present invention was completed by confirming collagen accumulation and PSC activation in vitro ) to confirm that the extract of Persimmon can be used as a pharmaceutical composition for the prevention and treatment of chronic pancreatitis.
  • An object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of chronic pancreatitis (CP) and novel pancreatitis (NJ) containing a novel use, specifically, the extract of N. persimmon (NJ) as an active ingredient It is.
  • CP chronic pancreatitis
  • NJ novel pancreatitis
  • Another object of the present invention to provide a food composition for preventing and improving chronic pancreatitis comprising the extract persimmon extract as an active ingredient.
  • the present invention provides a pharmaceutical composition for the prevention and treatment of chronic pancreatitis comprising the extract of Nardostachys jatamansi NJ as an active ingredient.
  • the present invention provides a food composition for preventing and improving chronic pancreatitis, including the extract of Nardostachys jatamansi NJ as an active ingredient.
  • the present invention provides a pharmaceutical composition for the prevention and treatment of chronic pancreatitis, comprising as an active ingredient extract of Persimmon (Nardostachys jatamansi NJ).
  • the chronic pancreatitis is preferably alcoholic chronic pancreatitis, and the composition further comprises a pharmaceutically acceptable carrier.
  • the extract of the persimmon extract is water or organic solvent extract of the root of the persimmon flavor, wherein the persimmon extract is 1 to the root of the persimmon fragrance More preferably, 20 times of water is added, extracted at 80 to 150 ° C. for 1 to 24 hours, and then filtered.
  • the extract of persimmon flavor of the present invention can be obtained by extracting the root of the persimmon incense with water or an organic solvent, the lower alcohol, acetone, chloroform, methylene chloride, ether, ethyl acetate, hexane and the like can be exemplified.
  • Lower alcohols include methanol, ethanol, propanol and butanol, with ethanol being most preferred.
  • the dried persimmon root dry matter or powder 1 at a temperature of 80-150 ° C., preferably 90-100 ° C. It may be extracted for 24 hours, preferably 2 to 6 hours, more preferably 2 hours and then filtered to prepare a hydrothermal extract of the persimmon root.
  • the organic solvent extract of the persimmon fragrance root may be prepared by adding 1 to 5 times, preferably 3 times the organic solvent to the dried persimmon root dry matter or powder, extracting at room temperature, and then filtrating the filtrate obtained under reduced pressure.
  • the organic solvent may be an ethanol or methanol extract.
  • the extraction process may be repeated two or more times as necessary, and the extract obtained after filtration may be freeze-dried or reduced-pressure drying to form a powder.
  • the pharmaceutical composition of the present invention may further include other pharmaceutically acceptable herbal medicines or extracts thereof to enhance the pharmacological effect.
  • an extract of the herbal medicine may be prepared according to the extraction method, and then added to the pharmaceutical composition, or the extract obtained by extracting by the above method after mixing the saenghyang root and the herbal medicine may be included in the composition.
  • 'pharmaceutically acceptable refers to a physiologically acceptable and, when administered to a human, usually does not cause an allergic or similar reaction.
  • the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelicae tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhei Rhizoma, Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Dermis (Aurantii nobilis Pericarpium), Taxa (Alismatis Rhizomaidi) ), Golden (Scutellariae Radix), Horyng (Hoelen), Peony (Paeoniae Radix), Bleach (Atractylodis Rhizoma alba), Peach (Phellodendri Cortex), Gardenia (Gardeniae Fructus), Pinelliae Tuber, Uncaria Ramuluset Uncus , Ponciri Fructus, Ginseng, Gingseng,
  • compositions according to the invention may further contain one or more pharmaceutically acceptable carriers, excipients or diluents.
  • Pharmaceutically acceptable carriers may further include, for example, carriers for oral administration or carriers for parenteral administration.
  • Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like.
  • carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose and glycols, and the like, and may further include stabilizers and preservatives.
  • Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid.
  • Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
  • Other pharmaceutically acceptable carriers may be referred to those described in the following documents (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).
  • the pharmaceutical composition for preventing or treating chronic pancreatitis of the present invention can be administered to any mammal, including humans.
  • it can be administered orally or parenterally.
  • Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal administration.
  • the pharmaceutical composition of the present invention may be administered transdermally.
  • 'transdermal administration' refers to the administration of the pharmaceutical composition of the present invention to cells or skin to deliver the active ingredient contained in the pharmaceutical composition for the prevention or treatment of chronic pancreatitis into the skin.
  • the pharmaceutical composition of the present invention may be prepared in an injectable formulation and administered by lightly pricking the skin with a 30 gauge thin injection needle, or directly applying to the skin.
  • composition of the present invention may be formulated into a preparation for oral or parenteral administration according to the route of administration as described above.
  • compositions of the present invention may be formulated using methods known in the art as powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions and the like.
  • oral formulations can be obtained by tablets or dragees by combining the active ingredients with solid excipients, milling them, adding suitable auxiliaries and then processing them into granule mixtures.
  • excipients examples include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol and starch, cellulose, including starch, corn starch, wheat starch, rice starch and potato starch, etc. Fillers such as celluloses, gelatin, polyvinylpyrrolidone, and the like, including methyl cellulose, sodium carboxymethylcellulose, hydroxypropylmethyl-cellulose, and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid or sodium alginate and the like may optionally be added as a disintegrant. Furthermore, the pharmaceutical composition of the present invention may further include an anticoagulant, a lubricant, a humectant, a perfume, an emulsifier, a preservative, and the like.
  • Formulations for parenteral administration may be formulated by methods known in the art in the form of injections, creams, lotions, external ointments, oils, humectants, gels, aerosols and nasal inhalants. These formulations are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a prescription generally known in all pharmaceutical chemistries.
  • the total effective amount of the extract of Persimmon Fragrance, the active ingredient of the composition of the present invention may be administered to a patient in a single dose, and may be administered in a fractionated treatment protocol administered for a long time in multiple doses. May be administered.
  • the pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the extent of the disease.
  • the preferred total dose of the sweet persimmon of the present invention may be about 100 ⁇ g to 5 mg, most preferably 500 ⁇ g to 1 mg per kg of patient body weight per day.
  • the dose of the extract is effective for taking into consideration the various factors such as the age, weight, health status, sex, severity of the disease, diet and excretion rate, as well as the route and frequency of treatment of the pharmaceutical composition Since the amount is determined, one of ordinary skill in the art will be able to determine the appropriate effective dosage according to the specific use of the sensational aroma as a prophylactic or therapeutic agent for chronic pancreatitis.
  • the pharmaceutical composition according to the present invention is not particularly limited to its formulation, route of administration and method of administration as long as the effect of the present invention is shown.
  • the present invention may be provided in the form of a food composition for the prevention and improvement of chronic pancreatitis comprising the extract of Nardostachys jatamansi NJ as an active ingredient.
  • the food composition of the present invention includes all forms such as functional foods, nutritional supplements, health foods and food additives. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
  • the persimmon extract of the present invention may be prepared by drinking tea, juice, and drink, or granulated, encapsulated, and powdered.
  • it can be prepared in the form of a composition by mixing with the extract of the sense of flavor of the present invention and known substances or active ingredients known to have the effect of preventing and improving chronic pancreatitis.
  • functional foods include beverages (including alcoholic beverages), fruits and processed foods (e.g. canned fruit, canned foods, jams, marmalade, etc.), fish, meat and processed foods (e.g. ham, sausage cornebipe) Etc.), breads and noodles (e.g. udon, soba noodles, ramen, spaghetti, macaroni, etc.), fruit juices, various drinks, cookies, syrups, dairy products (e.g. butter, cheese, etc.), edible vegetable oils, margarine, vegetable protein, It can be prepared by adding the extract of persimmon flavor of the present invention to retort foods, frozen foods, various seasonings (eg, miso, soy sauce, sauce, etc.).
  • fruits and processed foods e.g. canned fruit, canned foods, jams, marmalade, etc.
  • fish e.g. ham, sausage cornebipe
  • breads and noodles e.g. udon, soba noodles, ramen, spaghetti, macaroni, etc.
  • the persimmon aroma of the present invention in the form of food additives can be prepared in the form of powder or concentrate.
  • Pancreatic fibrosis has long been considered a late stage with little or no hope for improvement. With a more advanced understanding of the physiological mechanisms underlying chronic pancreatitis (CP) and the characteristics of astrocytic cells, the major working cells in this process, a more focused attention to the possibility of fibrosis regression was considered the only means. .
  • ACP alcoholic chronic pancreatitis
  • pancreatic acinar cells pancreatic acinar cells, collagen accumulation and pancreatic appearance
  • PSC Persimmon Fragrance Extract
  • AP is characterized by pain, edema, bleeding, saturation of acinar cells, necrosis, inflammation, and increased serum amylase and lipase; This feature is confused with chronic disease forms due to fibrosis, inflammation, collagen accumulation and reduced exocrine and endocrine function.
  • AP and CP differ in pathogenic causes, repetitive AP can gradually lead to CP (Ohashi, S. et al. (2006) Am. J. Physiol. Gastrointest. Liver Physiol. 290 , G772-781).
  • repeated administration of the cerulein model was limited in treatment time, severity, and similarity with humans.
  • mice were sufficient to induce ACP with a challenge given for 3 weeks, which was demonstrated by fibrosis, inflammation, and acinar cell destruction in the pancreas (see FIG. 1). Daily and free NJ consumption inhibited morphological damage to ACP (see FIG. 1). Amylase-positive cells are abundant in the pancreas, suggesting that exocrine function is functioning properly.
  • ACP The main question in the disease-physiology of ACP is whether the disease state can be reversed. Many clinicians often recommend patients to suppress alcohol, but this has little effect on patients. Prior research on how to improve the ACP By discontinue their alcohol intake did not find a substantial improvement (Apte, MV, etc. (2010) J. Gastroenterol Hepatol 25, 1816-1826;.. Gullo, L. , etc. (1988) Gastroenterology 95 , 1063-1068). In contrast to humans, rat AP and ACP models generally improve disease after lack of stimulation (Lugea, A. et al. (2006) Gastroenterology 131 , 885-899; Von Stamm, A. et al. (2010) Gut 60 , 238-246).
  • mice are not sufficient to demonstrate the mechanism of human CP.
  • regulation of PSC is a key factor (Masamune, A. et al. (2009) Clin. Gastroenterol. Hepatol. 7 , S48-54).
  • many studies have tried to modulate PSC by inactivating or killing PSC factors (Schwer, CI et al. (2008) J. Pharmacol. Exp. Ther. 327 , 863-871; Li, L. et al. (2011) Eur. J. Clin. Invest. 41 , 151-158; Madro, A. et al. (2008) J.
  • the present invention constituted as described above provides a novel use of persimmon aroma, chronic pancreatitis prevention and treatment composition comprising the persimmon extract as an active ingredient.
  • the composition comprising the extract of the present invention can be effectively used for the prevention and treatment of chronic pancreatitis because it effectively inhibits chronic pancreatitis caused by cerulein and ethanol.
  • Figure 1 shows the NJ effect on the morphology and tissue of the pancreas after ACP
  • A is a representative pancreatic external morphology
  • B is a representative H & E stained fragment of the pancreas
  • C is inflammation, edema, fibrosis, And histological fragments of the pancreas were recorded from 0 (normal) to 3 (severe) for the whole.
  • the photo shows a representative image of one experimental test with six mice per group. The results were similar in three additional experiments. First magnification ( ⁇ 200). * P ⁇ 0.05, the control group was treated with physiological saline.
  • Figure 2 shows the effect of NJ on acinar cell death during ACP, and the presence of acinar cells was detected by successive staining of pancreatic tissue fragments with amylase.
  • the photo shows a representative image of one experimental test with six mice per group. The results were similar in 3 additional experiments.
  • Figure 3 shows the effect of PSC activation and collagen accumulation during ACP, pancreatic tissue sections were sequentially stained with (A) ⁇ -SMA and (C) collagen to detect activated PSCs.
  • the photo shows a representative image of one experimental test with six mice per group. First magnification ( ⁇ 400).
  • (B) measured pancreatic mRNA levels of ⁇ -SMA, fibronectin and TGF- ⁇ by quantitative RT-PCR. The data represents the mean SE SE of 6 mice in each group. The results were similar in three additional experiments. * P ⁇ 0.05, control group treated with saline solution
  • Figure 4 shows the effect of NJ on PSC activation in isolated PSC, PSC was isolated from rat pancreas and culture activated for 3 weeks. On day 21, NJ was treated for 24 hours. Then, (A) desmin and (B) ⁇ -SMA were treated successfully to detect PSC isolation and activation. First magnification ( ⁇ 400). (C) detected Western blot expression of ⁇ -SMA. (D) quantified cytokine mRNA expression by PSC by real-time RT-PCR. The photograph shows a representative image of one experiment. The results were similar in three additional experiments. * P ⁇ 0.05, the control group was treated with physiological saline.
  • Cerulean Tris-HCl, NaCl, collagen, DAPI, hematoxylin, eosin, xylene, ethanol, cerulein and Triton X-100 are Sigma-Aldrich (St. Louis, MO, USA).
  • ⁇ -smooth muscle actin (SMA), collagen, and desmine were purchased from Abcam (UK).
  • Amylase and GAPDH were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
  • mice All animal experiments were performed according to a protocol approved by Wonkwang University Animal Care Committee. Experimental animals purchased 15-20 g body weight 6-8 week old C57BL / 6 mouse females (15-20 g body weight) (Orient Bio). All experimental animals were bred for 7 days in a breeding room with a room temperature of 23 ⁇ 2 °C and a contrast cycle of 12 hours. The experimental animals were fed with standard feed and water as ad libitum for 7 days to adapt to the environment, and then randomly divided into control and experimental groups. Each mouse was fasted for 18 hours before inducing alcoholic chronic pancreatitis (ACP).
  • ACP alcoholic chronic pancreatitis
  • Dried persimmon roots were purchased from General Herbs (Omni Herb, Seoul, Korea). Identification of the herb was confirmed in the Korean drug test laboratory. Voucher specimens (NO; Oh / wh / nj-43) were deposited in Wonkwang University Oriental Medicine Plant Botanical Laboratory.
  • the distilled root was put in distilled water of about 10 times and boiled for about 2 hours, and then the extract was filtered and lyophilized at -70 ° C to powder.
  • the powder was extracted with distilled water, filtered and stored at 4 ° C.
  • the powder was dissolved in physiological saline and used at the required concentration.
  • Immobilized pancreatic tissue was embedded in paraffin, cut into 4 ⁇ m sections and stained with haematoxyl-eosin for standard histological examination. Immunohistochemical staining with amylase, collagen or ⁇ -SMA was performed using a DAB immunohistohemical kit (DAKO, Cytomation, Denmark). Incubation of PSC with anti- ⁇ -SMA, or desmin, followed by incubation with Alexa Fluors 568 goat-anti rabbit IgG (1: 2,000, Invitrogen, Carlsbad, Calif., USA) for 1 hour at room temperature, DAPI, ⁇ - Immunofluorescence detection of SMA or desmine was performed. The slides were mounted with mounting medium equipped with DAPI (Vector Laboratories, Burlingame, CA, USA).
  • mRNA messenger RNA
  • Target cytokine transcription was analyzed by RT-PCR in mouse pancreatic tissue and PSC.
  • Total RNA was isolated from pancreas and PSC of mice using TriZol (Invitrogen, Carlsbad, CA, USA) and reverse transcription was performed using SuperScript II RT (Invitrogen, Carlsbad, CA, USA).
  • TaqMan quantitative RT-PCR was performed using the ABI stepone plue system according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA).
  • HGPRT hypoxanthine-guanine phosphoribosyltransferase
  • the mixed interface was harvested, and the cells were washed and then in DMEM containing 10% fetal bovine serum (FBS), 4 mM glutamine, and antibiotics (penicillin 100 U / ml, streptomycin 100 mg / ml). Resuspend. After reaching confluency, cells were harvested and replated at the same seed density. All experiments were performed using culture-harvested cells (2-4 generations). PSCs were incubated in serum-deficient media 24 hours prior to the addition of experimental reagents.
  • FBS fetal bovine serum
  • 4 mM glutamine fetal bovine serum
  • antibiotics penicillin 100 U / ml, streptomycin 100 mg / ml
  • the lysate was boiled in the same buffer (62.5 mM Tris-HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS), 20% glycerol, and 10% 2-mercaptoethanol). Then, proteins in cell lysate were separated by 10% SDS-PAGE and transferred to nitrocellulose membrane. After transfer of the protein, the membrane was blocked with 5% skim milk of PBST (PBS-Tween-20) for 2 hours at room temperature, and then reacted with ⁇ -SMA and antibody overnight.
  • PBST PBS-Tween-20
  • each blot is reacted with peroxidase-linked secondary antibody for 1 hour and the antibody-specific protein using an improved chemiluminescence detection system (Amersham, Piscataway, NJ) according to the manufacturer's recommended protocol was visualized.
  • pancreatic stromal edema pancreatic stromal edema, inflammation, infiltration, and pancreatic fibrosis were demonstrated (FIG. 1).
  • ACP lost its characteristic morphology and had edema characteristics rather than the normal pancreas.
  • NJ treatment at 5 or 10 mg / ml significantly reduced external morphological edema of the pancreas (FIG. 1).
  • FIG. 1B in histological examination, NJ treatment did not show significant protection against ACP challenge.
  • FIG. 1B In order to further investigate the exact effect of NJ on ACP, we measured the survival of pancreatic acinar cells via amylase release.
  • ACP challenged mice demonstrated disruption of pancreatic acinar cells, as indicated by reduced amylase.
  • NJ treatment significantly inhibited acinar cell death and destruction (FIG. 2).
  • PSCs express intermediate filament proteins such as desmin (13).
  • PSCs express intermediate fiber proteins such as desmin (Omary, MB et al. (2004) N. Engl. J. Med. 351 , 2087-2100). As reported previously, isolated PSCs had a desmin positive response, indicating that the isolated cells were PSCs (FIG. 4A). Upon 3-week incubation of PSCs, the PSCs are activated and express ⁇ -SMA (FIG. 4B). However, NJ treatment inhibited the expression of ⁇ -SMA in PSCs (FIGS. 4B and 4C). NJ treatment also inhibited mRNA expression of fibrosis-related genes such as ⁇ -SMA, fibronectin, and TGF- ⁇ in PSCs.
  • the present invention provides a composition for the prevention and treatment of chronic pancreatitis, which comprises the extract of Persimmon as an active ingredient as a novel use of persimmon. Since the composition of the present invention effectively inhibits chronic pancreatitis caused by cerulein, it can be effectively used for the prevention and treatment of chronic pancreatitis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une nouvelle utilisation de Nardostachys jatamansi (NJ), plus spécifiquement une composition pharmaceutique pour prévenir et traiter la pancréatite chronique qui comprend un extrait de Nardostachys jatamansi en tant que substance active ou composition alimentaire pour prévenir ou améliorer la pancréatite chronique. La composition de la présente invention supprime efficacement la pancréatite chronique induite par la caéruléine et l'éthanol, et peut donc être efficacement utilisée dans la prévention et le traitement de la pancréatite chronique.
PCT/KR2013/000357 2013-01-17 2013-01-17 Composition pharmaceutique pour prévenir et traiter la pancréatite chronique comprenant un extrait de nardostachys jatamansi en tant que substance active Ceased WO2014112663A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2013/000357 WO2014112663A1 (fr) 2013-01-17 2013-01-17 Composition pharmaceutique pour prévenir et traiter la pancréatite chronique comprenant un extrait de nardostachys jatamansi en tant que substance active

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2013/000357 WO2014112663A1 (fr) 2013-01-17 2013-01-17 Composition pharmaceutique pour prévenir et traiter la pancréatite chronique comprenant un extrait de nardostachys jatamansi en tant que substance active

Publications (1)

Publication Number Publication Date
WO2014112663A1 true WO2014112663A1 (fr) 2014-07-24

Family

ID=51209748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/000357 Ceased WO2014112663A1 (fr) 2013-01-17 2013-01-17 Composition pharmaceutique pour prévenir et traiter la pancréatite chronique comprenant un extrait de nardostachys jatamansi en tant que substance active

Country Status (1)

Country Link
WO (1) WO2014112663A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018993A1 (fr) * 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Composition therapeutique a base d'herbes
US20040265335A1 (en) * 2003-05-19 2004-12-30 Amazon Biotech Inc. Herbal composition and method of treating HIV infection
US20070122495A1 (en) * 2005-11-28 2007-05-31 Sahajanand Biotech Pvt. Ltd. Herbal composition to improve psychological functions as an anxiolytic, tranquilizer, and non-narcotic sedative, as well as other physiological functions
KR20100095838A (ko) * 2009-02-23 2010-09-01 주식회사한국전통의학연구소 감송향 추출물을 활성성분으로 포함하는 급성 췌장염의 예방 및 치료용 약학적 조성물
KR20110098500A (ko) * 2010-02-26 2011-09-01 전북대학교산학협력단 감송향 추출물을 유효성분으로 포함하는 제１형 당뇨병 예방 및 치료용 조성물과 이를 포함하는 건강식품
KR20120111109A (ko) * 2011-03-31 2012-10-10 주식회사한국전통의학연구소 감송향 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018993A1 (fr) * 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Composition therapeutique a base d'herbes
US20040265335A1 (en) * 2003-05-19 2004-12-30 Amazon Biotech Inc. Herbal composition and method of treating HIV infection
US20070122495A1 (en) * 2005-11-28 2007-05-31 Sahajanand Biotech Pvt. Ltd. Herbal composition to improve psychological functions as an anxiolytic, tranquilizer, and non-narcotic sedative, as well as other physiological functions
KR20100095838A (ko) * 2009-02-23 2010-09-01 주식회사한국전통의학연구소 감송향 추출물을 활성성분으로 포함하는 급성 췌장염의 예방 및 치료용 약학적 조성물
KR20110098500A (ko) * 2010-02-26 2011-09-01 전북대학교산학협력단 감송향 추출물을 유효성분으로 포함하는 제１형 당뇨병 예방 및 치료용 조성물과 이를 포함하는 건강식품
KR20120111109A (ko) * 2011-03-31 2012-10-10 주식회사한국전통의학연구소 감송향 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물

Similar Documents

Publication Publication Date Title
KR101023780B1 (ko) 감송향 추출물을 활성성분으로 포함하는 급성 췌장염의 예방 및 치료용 약학적 조성물
WO2012134169A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait de semence de gleditsiae
KR101624704B1 (ko) 탈모 또는 전립선 비대증의 예방, 치료 또는 개선용 약학 조성물 및 건강기능식품용 조성물
KR20090094619A (ko) 면역증강, 또는 세균성 장염이나 콕시듐증의 예방 또는치료용 조성물
KR101500582B1 (ko) 감송향 추출물을 활성성분으로 포함하는 만성 췌장염의 예방 및 치료용 약학적 조성물
WO2014112663A1 (fr) Composition pharmaceutique pour prévenir et traiter la pancréatite chronique comprenant un extrait de nardostachys jatamansi en tant que substance active
KR101667873B1 (ko) 한방 추출물 또는 이의 분획물을 포함하는 파킨슨 질환의 예방 또는 치료용 약학적 조성물
KR20240047864A (ko) 부추와 곤드레 추출물을 유효성분으로 하는 항비만 조성물 및 이의 제조 방법물
KR101752484B1 (ko) 백축 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
KR20230046054A (ko) 황금 및 황련 추출물을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
KR20120021283A (ko) 육두구 추출물을 포함하는 전립선암 치료용 조성물 및 기능성 식품
KR20210157522A (ko) 보중익기탕 추출물을 유효성분으로 포함하는 당뇨병성 신장병증의 예방, 개선 또는 치료용 조성물
WO2012134250A2 (fr) Composition pour le traitement du cancer du rein et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR101385658B1 (ko) 익지인 추출물을 포함하는 전립선암 치료용 조성물 및 기능성 식품
KR20150118049A (ko) 감송향 추출물을 활성성분으로 포함하는 치주질환 예방 및 치료용 조성물
WO2013147340A1 (fr) Composition et complément alimentaire pour traiter le cancer du poumon, contenant un extrait d'encens
WO2012134167A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait d'eriobotriae folium
WO2012134251A2 (fr) Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20120021281A (ko) 고량강 추출물을 포함하는 전립선암 치료용 조성물 및 기능성 식품
WO2014077432A1 (fr) Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques
WO2014069692A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait d'inula britannica var. chinensis
Claw Capsicum
KR20120122404A (ko) 괄루근 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20120058395A (ko) 청피 추출물을 포함하는 전립선암 치료용 조성물 및 기능성 식품
KR20120021282A (ko) 비파엽 추출물을 포함하는 전립선암 치료용 조성물 및 기능성 식품

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13871614

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13871614

Country of ref document: EP

Kind code of ref document: A1